REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
基本信息
- 批准号:6030356
- 负责人:
- 金额:$ 8.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-07-01 至 2001-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The primary goal of these studies is to investigate the regulation of
inducible tissue factor pathway inhibitor (TFPI) gene expression in
monocytes and fibroblasts. Using Northern blotting analysis and TEPI
assays, the applicant had previously demonstrated that endothelium is the
primary physiologic site of TFPI synthesis and that monocytes and
fibroblasts normally express none to very little TFPI. However, the
applicant's preliminary data indicate that TFPI expression is vastly
upregulated in adherent monocytes and monocytic U93 cells. In this
proposal, the applicant will define the adhesion response elements in the
TFPI gene that upregulate TFPI expression in monocytes and U937 cells. The
applicant has also found that fibroblasts significantly upregulate TFPI
expression in response to serum and in this proposal she plans to define
the serum response elements that upregulate its expression in fibroblasts.
preliminary data also suggest that adherent monocytes and U937 cells,
serum-stimulated fibroblasts and several transformed cell lines that
express TFPI also express GATA-2 transcription factor. In gel mobility
shift assays, factor(s) from nuclear extracts of HepG2 cells (a transformed
cell line that expresses both TFPI and GATA-2 transcription factor) appear
to bind to a DNA fragment from the TFPI promoter region containing a
putative GATA motif. Additionally, GATA-2 transcription factor antisense
oligomers significantly decreased the expression of TFPI and GATA-2
transcription factor mRNA in adherent UJ937 cells. Thus GATA-2
transcription factor may be required for TFPI gene expression. This
possibility will be further tested in monocytes and fibroblasts by the use
of sense and antisense strategies.
Preliminary data was generated under the guidance of the sponsor, Paul
Bajaj, who is an expert ina the field of coagulation and thrombosis. The
applicant will continue to work in the laboratory of Paul Bajaj for the
proposed studies. She will also receive constant guidance from the co-
sponsor, Joel Eissenberg who is an experienced and recognized molecular
biologist. The applicant will meet frequently with the advisory committee
(Drs. Sly, Huang, Hyers, and Payvar) to seek guidance and discuss her
progress. Thus ample resources and vast expertise is available to the
applicant to perform the proposed studies. It is anticipated that the
studies will yield important new information on the regulation of inducible
TEPI gene expression during an inflammatory response.
这些研究的主要目的是调查
诱导型组织因子途径抑制物(TFPI)基因的表达
单核细胞和成纤维细胞。使用Northern blotting分析和TEPI
化验,申请人以前曾证明内皮细胞是
TFPI合成的主要生理部位以及单核细胞和
成纤维细胞通常不表达或很少表达TFPI。然而,
申请人的初步数据表明,TFPI的表达大量
在贴壁的单核细胞和单核细胞U93细胞中上调。在这
建议书中,申请人将定义附着力反应要素
TFPI基因上调单核细胞和U937细胞中TFPI的表达。这个
申请人还发现,成纤维细胞显著上调TFP I
表达对血清的反应,在这项提案中,她计划定义
在成纤维细胞中上调其表达的血清反应元件。
初步数据还表明,贴壁的单核细胞和U937细胞,
血清刺激的成纤维细胞和几个转化的细胞系
表达TFPI还表达GATA-2转录因子。在凝胶流动性方面
肝癌细胞(转化株)细胞核提取液中S因子的位移分析
同时表达TFPI和GATA-2转录因子的细胞系)出现
结合TFPI启动子区域的DNA片段,该DNA片段包含
推定的GATA主题。此外,GATA-2转录因子反义
寡聚体显著降低TFPI和GATA-2的表达
贴壁UJ937细胞中转录因子mRNA的表达。因此,GATA-2
转录因子可能是TFPI基因表达所必需的。这
这种可能性将在单核细胞和成纤维细胞中进一步测试
正义和反正义的策略。
初步数据是在发起人保罗的指导下产生的
他是凝血和血栓领域的专家。这个
申请者将继续在Paul Bajaj的实验室工作
建议进行的研究。她还将接受合作伙伴的持续指导-
赞助商,Joel Eissenberg,他是一位经验丰富和公认的分子
生物学家。申请人将经常与咨询委员会举行会议。
(Sly、Huang、Hyers和Payvar博士)寻求指导并讨论她
进步。因此,充足的资源和丰富的专业知识可供
申请人须进行拟进行的研究。据预计,
研究将在诱导物的监管方面产生重要的新信息
炎症反应过程中TEPI基因的表达。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Madhu Satya Bajaj其他文献
Madhu Satya Bajaj的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Madhu Satya Bajaj', 18)}}的其他基金
Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
- 批准号:
7589884 - 财政年份:2009
- 资助金额:
$ 8.53万 - 项目类别:
Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
- 批准号:
7792289 - 财政年份:2009
- 资助金额:
$ 8.53万 - 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
- 批准号:
6181932 - 财政年份:1996
- 资助金额:
$ 8.53万 - 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
- 批准号:
2211397 - 财政年份:1996
- 资助金额:
$ 8.53万 - 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
- 批准号:
2445017 - 财政年份:1996
- 资助金额:
$ 8.53万 - 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
- 批准号:
2734937 - 财政年份:1996
- 资助金额:
$ 8.53万 - 项目类别:
相似海外基金
Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
- 批准号:
22K09003 - 财政年份:2022
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
- 批准号:
21K07762 - 财政年份:2021
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
- 批准号:
20K16927 - 财政年份:2020
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
- 批准号:
20H00526 - 财政年份:2020
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
- 批准号:
20K21245 - 财政年份:2020
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
- 批准号:
G0900887/1 - 财政年份:2011
- 资助金额:
$ 8.53万 - 项目类别:
Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
- 批准号:
05558090 - 财政年份:1993
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
- 批准号:
04453031 - 财政年份:1992
- 资助金额:
$ 8.53万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)